“常青”药品专利的司法控制:加拿大“礼来”案评析及其镜鉴  

Judicial Control for Evergreening Patent Medicines: An Analysis of Canadian Eli Lilly Case and Reference

作　　者：李晓秋[1,2,3] 

机构地区：[1]中南财经政法大学法学博士后流动站 [2]重庆大学法学院 [3]重庆市高级人民法院民三庭

出　　处：《知识产权》2015年第10期130-135,共6页Intellectual Property

基　　金：2014年国中国博士后基金特别资助项目"专利权运营异化的法律治理"(2014T70762)的阶段性成果

摘　　要："常青"药品专利打破了药品专利权人、仿制药生产商与社会公众之间的利益平衡,司法控制是恢复利益平衡的重要手段之一。在2015年的"礼来"案中,加拿大联邦法院认为,诉争专利并非属于"显而易见型"重复授权专利,否认原告以"常青"专利方式延长专利垄断权,确认专利有效。我国有必要借鉴加拿大的司法实践,阻遏"常青"药品专利及其逆效应。It will likely happen for evergreen patent medicine to break the balance of interests among drugs patentees, genetic drugs producers and patients, and judicial control is one of important approaches to recovering all parties＇ balance of interests. In the very beginning of 2015, the Federal Court of Canada delivered a judgment in favor of applicant in Eli Lilly Canada Inc. v. Mylan Pharmaceuticals ULC., refusing the respondent＇s claim based on litigated patent invalidity for obviousness-type double patenting and meeting the requirements of Evergreen Patent to extend the exclusive tight. It is of necessity to learn from Canada to prevent the Evergreen Patent along with the inverse effects from injuring pharmacy industry.

关 键 词：制药产业 “常青”专利 专利无效“礼来”案 利益平衡 

分 类 号：D913[政治法律—民商法学]